IL-13Rα2 Antibody (YY-23Z): sc-74160
- IL-13Rα2 Antibody (YY-23Z) is a mouse monoclonal IgG1, cited in 2 publications, provided at 100 µg/ml
- raised against an extracellular domain of IL-13Rα2 of human origin
- recommended for detection of IL-13Rα2 of human origin by WB and IP
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for IL-13Rα2 Antibody (YY-23Z). This work is in progress.
QUICK LINKS
SEE ALSO...
IL-13Rα2 Antibody (YY-23Z) is a mouse monoclonal IgG1 antibody that detects IL-13Rα2 in human samples through western blotting (WB) and immunoprecipitation (IP) applications. IL-13Rα2 plays a pivotal role in modulating the immune response, particularly in allergic reactions and asthma, by acting as a decoy receptor for interleukin-13 (IL-13). This decoy function prevents IL-13 from binding to IL-13Rα1, thereby inhibiting downstream signaling pathways that can lead to airway hyper-responsiveness and inflammation. IL-13Rα2 expression is notably upregulated in response to pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNFα) and IL-4, which further emphasizes IL-13Rα2′s role in the negative regulation of IL-13 signaling. Understanding IL-13Rα2 expression and IL-13 interaction is essential for developing therapeutic strategies aimed at alleviating allergic conditions and related diseases. Anti-IL-13Rα2 antibody (YY-23Z) is an invaluable tool for researchers investigating immune regulation mechanisms and allergic disease pathophysiology.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
IL-13Rα2 Antibody (YY-23Z) References:
- IL-13Ralpha2 reverses the effects of IL-13 and IL-4 on bronchial reactivity and acetylcholine-induced Ca+ signaling. | Kellner, J., et al. 2007. Int Arch Allergy Immunol. 142: 199-210. PMID: 17106207
- IL-13Rα2 uses TMEM219 in chitinase 3-like-1-induced signalling and effector responses. | Lee, CM., et al. 2016. Nat Commun. 7: 12752. PMID: 27629921
- Inhibition of IL-13 and IL-13Rα2 Expression by IL-32θ in Human Monocytic Cells Requires PKCδ and STAT3 Association. | Pham, TH., et al. 2019. Int J Mol Sci. 20: PMID: 31010051
- Scratching Counteracts IL-13 Signaling by Upregulating the Decoy Receptor IL-13Rα2 in Keratinocytes. | Ulzii, D., et al. 2019. Int J Mol Sci. 20: PMID: 31284553
- Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers. | Liang, R., et al. 2022. Drug Deliv. 29: 1620-1630. PMID: 35612318
- IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma. | Rechberger, JS., et al. 2022. Pharmaceutics. 14: PMID: 35631512
- Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with 89Zirconium oxine for PET imaging. | Leland, P., et al. 2023. J Transl Med. 21: 367. PMID: 37286997
- The mechanism of IL-13 targeting IL-13Rα2 in regulating oral mucosal FBs through PI3K/AKT/mTOR. | Wang, L., et al. 2024. Oral Dis. 30: 3142-3154. PMID: 37897109
- IL-13Rα2-targeted CAR T cells show promise in patients with recurrent high-grade gliomas. | Killock, D. 2024. Nat Rev Clin Oncol. 21: 335. PMID: 38514882
- Novel tri-specific T-cell engager targeting IL-13Rα2 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cells. | Park, DH., et al. 2024. J Immunother Cancer. 12: PMID: 39622583
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IL-13Rα2 Antibody (YY-23Z) | sc-74160 | 100 µg/ml | $316.00 |